Reported resultsCompany-reported
What was reported
SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 3, 2026 · Open the source ↗
What the evidence supports
ClearPoint Neuro published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $10.9 million | “• Reported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue declined 15% in the quarter, primarily due to a decrease in products shipped to biopharma customers supporting new trial initiations compared to the second quarter a year ago.” Mentions: revenue |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineClearPoint Neuro Reports Second Quarter 2026 ResultsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 3, 2026 · Open the source ↗
Press release lead paragraphSOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 3, 2026 · Open the source ↗
Amount stated in press release• Reported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue declined 15% in the quarter, primarily due to a decrease in products shipped to biopharma customers supporting new trial initiations compared to the second quarter a year ago.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 3, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
ClearPoint Neuro Reports Second Quarter 2026 Results
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.